Attention Deficit and Hyperkinetic Disorders – Cannabis Research

Attention Deficit and Hyperkinetic Disorders Research Dashboard


Primary Studies


Related Studies


Total Studies

Clinical Studies


Clinical Meta-analyses


Double-blind human trials


Clinical human trials

Pre-Clinical Studies




Animal studies


Laboratory studies

What am I missing as a non-subscriber?

To see a full dashboard with study details and filtering, go to our DEMO page.

As a subscriber, you will be able to access dashboard insights including chemotype overviews and dosing summaries for medical conditions and organ system and receptor breakdowns for cannabinoid and terpene searches. Study lists present important guidance including dosing and chemotype information with the ability to drill down to the published material. And all outputs are fully filterable, to help find just the information you need. Stay up-to-date with the science of cannabis and the endocannabinoid system with CannaKeys.

CannaKeys has 37 studies associated with Attention Deficit and Hyperkinetic Disorders.

Here is a small sampling of Attention Deficit and Hyperkinetic Disorders studies by title:

Components of the Attention Deficit and Hyperkinetic Disorders Research Dashboard

  • Dosing information available for Attention Deficit and Hyperkinetic Disorders
  • Chemotype guidance for treating Attention Deficit and Hyperkinetic Disorders with cannabis
  • Synopsis of cannabis research for Attention Deficit and Hyperkinetic Disorders
  • Individual study details for Attention Deficit and Hyperkinetic Disorders

Ready to become a subscriber? Go to our PRICING page.

Select New Condition

Search By Keyword

Filter Condition

Members can filter by the following criteria:

  • Study Type
  • Chemotype
  • Cannabinoids & Endocannabinoids
  • Terpenes
  • Receptors
  • Ligands
  • Study Result
  • Year of Publication

Overview - Attention Deficit and Hyperkinetic Disorders

Description of Attention Deficit and Hyperkinetic Disorders

Orthodox medicine is not sure what causes ADHD nor does it provide a cure. Current hypothesis suggests a combination of factors including nutrition (or the lack of it), junk food (i.e. especially refined or artificial sugars, artificial taste enhancers such as glutamate), environmental toxins (i.e. lead, smoking, electro-pollution, organophosphate insecticides), epigenetics, genetic (i.e. genes involved in dopamine production or use), or certain social conditions (i.e. forms of PTSD). The disorder is primarily managed with mind-altering psychoactive drugs aimed at increasing the neurotransmitters dopamine and norepinephrine. The increase is achieved by given drugs such as Adderall or Desoxyn (amphetamines-based salts), Strattera (norepinephrine reuptake inhibitor), or Ritalin (dopamine and norepinephrine reuptake inhibitors)—drugs which are basically and as such (especially Desoxyn which is methamphetamine) carry with them a high-risk drug for abuse and addiction. Drugs are delivered orally as pills, skin patches, or as a liquid. Adverse effects of psycho-stimulants may include for instance a lack of appetite, insomnia, tics, feeling 'high' or 'funny,' psychotic episodes (hearing voices, hallucination, paranoia), or cardio-vascular problems.

Disease Classification

Condition: ADD and ADHD
Disease Family: Mental Disorders
Organ System: Mental/Emotional System, Nervous System
ICD-10 Chapter: Mental and Behavioural Disorders
ICD-10 Code: F90

Attention Deficit and Hyperkinetic Disorders Symptoms:

Difficulty concentrating, hyperactivity, restlessness, poor impulse control, impatience, disruptive behavior

Also known as:

ADD, ADHD, Attention Deficit Disorder, Attention Deficit Hyperactvity Disorder

Drug Interactions

THC Interaction with Pharmaceutical Drugs

  • THC can enhance the effects of drugs that cause sedation and depress the central nervous system, such as benzodiazepines, barbiturates, and alcohol, for example. 
  • THC is metabolized by and an inhibitor of a number of enzymatic liver pathways referred to as cytochrome P450. There are more than 50 enzymes belonging to this enzyme family, a number of which are responsible for the breakdown of common drugs such as antidepressants (e.g. amitriptyline, doxepine, fluvoxamine), antipsychotics (haloperidol, clozapine, stelazine), beta-blockers (e.g. propranolol), bronchodilators (e.g. theophylline), or bloodthinners (e.g. warfarin).  Thus patients taking these classes of medication may find that THC increases the concentration and effects of these drugs as well as the duration of their effects.
  • Clinical observation suggests no likely interactions with other pharmaceuticals at a total daily dose of up to 20mg THC.

CBD Interaction with Pharmaceutical Drugs

  • CBD may alter action on metabolic enzymes (certain drug-transport mechanisms), and as such may alter interactions with other drugs, some of which may produce therapeutic or adverse effects. For instance, CBD interacts with the enzyme cytochrome P450 3A4 and cytochrome P450 2C19, increasing the bioavailability of anti-epileptic drugs such as clobazam (a benzodiazepine). This makes it possible to achieve the same results at significantly lower dosages, reducing treatment costs and risks of adverse effects. 
  • Groups of drugs affected include: anti-epileptic drugs, psychiatric drugs, and drugs affecting metabolic enzymes, for example.
  • Clinical observations suggest no likely interactions with other pharmaceuticals at a total daily dose of up to 100mg CBD

Dosing Considerations

THC Dosage Considerations

  • THC micro dose:  0.1 mg to 0.4 mg
  • THC low dose:  0.5 mg to 5 mg
  • THC medium dose:  6 mg to 20 mg
  • THC high dose:  21 mg to 50+ mg

CBD Dosage Considerations

  • CBD low dose:  0.4 mg to 19 mg
  • CBD medium dose: 20 mg to 99 mg
  • CBD high dose:  100 mg to 800+ mg (upper limits tested ~1,500mg)

Disclaimers: Information on this site is provided for informational purposes only and is not meant to substitute for the advice provided by your own physician or other medical professional. You should not use the information contained herein for diagnosing a health problem or disease. If using a product, you should read carefully all product packaging. If you have or suspect that you have a medical problem, promptly contact your health care provider.

Information on this site is based on scientific studies (human, animal, or in vitro), clinical experience, or traditional usage as cited in each article. The results reported may not necessarily occur in all individuals. For many of the conditions discussed, treatment with prescription or over-the-counter medication is also available. Consult your physician, nutritionally oriented health care practitioner, and/or pharmacist for any health problem and before using any supplements or before making any changes in prescribed medications.